Significant Ownership of Trails Edge Capital Partners, LP
- Signature - Title
- By: Trails Edge Capital Partners, LLC, GP of Trails Edge Capital Partners, LP /s/ Ortav Yehudai - Ortav Yehudai / Chief Investment Officer of Trails Edge Capital Partners, LLC
- Location
- Atlanta, GA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Trails Edge Capital Partners, LP.
Follow Filing Activity
Follow Trails Edge Capital Partners, LP and return when a new Schedule 13D/G filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Continue schedule research
Related filing hubs for this reporting manager, useful for reinforcing crawl paths across the schedule cluster.
Significant Ownership of Trails Edge Capital Partners, LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| PMN | ProMIS Neurosciences Inc. | Common Shares, no par value per share | 9.9% | $6,347,644 | 933,477 | Trails Edge Capital Partners, LP | 03 Feb 2026 | ||
| VTVT | vTv Therapeutics Inc. | Common Stock, par value $0.01 per share | 9.9% | $5,108,040 | 340,536 | Trails Edge Capital Partners, LP | 29 Aug 2025 | ||
| SNSE | Sensei Biotherapeutics, Inc. | Common Shares, no par value per share | 9.9% | $1,217,257 | 126,010 | Trails Edge Capital Partners, LP | 18 Feb 2026 | ||
| IMUX | Immunic, Inc. | Common Shares, no par value per share | 8.7% | $6,986,940 | 11,454,000 | Trails Edge Capital Partners, LP | 17 Feb 2026 | ||
| XFOR | X4 Pharmaceuticals, Inc. | Common Stock, par value $0.001 per share | 5.8% | $20,333,894 | +$11,320,168 | 5,227,222 | +126% | Trails Edge Capital Partners, LP | 31 Dec 2025 |
| NGNE | Neurogene Inc. | Common Stock | 5.1% | $20,794,650 | 785,000 | Trails Edge Capital Partners, LP | 08 Dec 2025 | ||
| IKT | Inhibikase Therapeutics, Inc. | Common Stock, $0.001 par value | 5.1% | $9,525,057 | 6,145,198 | Trails Edge Capital Partners, LP | 23 Dec 2025 | ||
| LBRX | LB Pharmaceuticals Inc | Common Stock, par value $0.0001 | 5% | $20,964,420 | 1,268,265 | Trails Edge Capital Partners, LP | 24 Dec 2025 | ||
| MIST | Milestone Pharmaceuticals Inc. | Common Shares | 4.3% | $9,013,333 | -$6,226,884 | 5,333,333 | -41% | Trails Edge Capital Partners, LP | 20 Mar 2026 |
Schedules 13D/G Reported by Trails Edge Capital Partners, LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.